Rotating Boulder Fund

Rotating Boulder Fund is a fund management company that specializes in finance, asset management, and equity investment. It offers a range of services aimed at optimizing investment strategies and managing assets effectively. The company focuses on providing tailored financial solutions to meet the diverse needs of its clients, ensuring a strategic approach to fund management. By integrating various financial disciplines, Rotating Boulder Fund aims to enhance investment performance and deliver value in a competitive marketplace.

Donald Dai

Managing Partner

6 past transactions

RNAimmune

Series A in 2022
RNAimmune, Inc. is a biopharmaceutical company based in Gaithersburg, Maryland, that focuses on developing messenger RNA (mRNA) therapeutics and vaccines. The company employs mRNA as a data carrier to instruct the human body to produce proteins that can combat various diseases, including cancer, infectious diseases, and rare conditions. RNAimmune is a spin-off from Sirnaomics, Inc. and possesses exclusive rights to the proprietary Polypeptide Lipid Nanoparticle (PLNP) technology, which facilitates mRNA delivery. Additionally, the company has created a proprietary artificial intelligence algorithm known as ALEPVA, designed for antigen prediction and vaccine design. By integrating multiple established platform technologies, RNAimmune aims to build a comprehensive mRNA drug discovery and development platform, enhancing its pipeline to address significant unmet medical needs.

SparX Group

Series B in 2021
SparX Group is a biotech firm that develops innovative anticancer biologics through bispecific antibodies and drug conjugates.

Sirnaomics

Series E in 2021
Sirnaomics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing targeted therapeutics for significant human diseases using RNA interference (RNAi) technology. Founded in 2007 and headquartered in Gaithersburg, Maryland, with additional offices in Cambridge, Massachusetts, and facilities in Suzhou and Guangzhou, China, Sirnaomics is dedicated to addressing critical medical needs in oncology, anti-fibrotic therapeutics, and viral infections. The company's product portfolio includes several small interfering RNA (siRNA) therapeutics such as STP705 for scar reduction, STP909 for colon cancer, and STP900 for HPV and cervical cancer, among others. Sirnaomics employs proprietary Polypeptide Nano-Particle (PNP) technology to enhance drug delivery, allowing effective targeting of the tumor microenvironment and various cell types, particularly in the liver. Through its innovative approach, Sirnaomics aims to create impactful treatments for diseases with large market opportunities.

Sirnaomics

Series D in 2020
Sirnaomics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing targeted therapeutics for significant human diseases using RNA interference (RNAi) technology. Founded in 2007 and headquartered in Gaithersburg, Maryland, with additional offices in Cambridge, Massachusetts, and facilities in Suzhou and Guangzhou, China, Sirnaomics is dedicated to addressing critical medical needs in oncology, anti-fibrotic therapeutics, and viral infections. The company's product portfolio includes several small interfering RNA (siRNA) therapeutics such as STP705 for scar reduction, STP909 for colon cancer, and STP900 for HPV and cervical cancer, among others. Sirnaomics employs proprietary Polypeptide Nano-Particle (PNP) technology to enhance drug delivery, allowing effective targeting of the tumor microenvironment and various cell types, particularly in the liver. Through its innovative approach, Sirnaomics aims to create impactful treatments for diseases with large market opportunities.

iSpace China

Series B in 2020
iSpace China, founded in 2016 and headquartered in Beijing, specializes in the development of commercial launch vehicles and space shuttles for aerospace customers globally. The company focuses on providing innovative solutions for the burgeoning commercial space industry, aiming to meet the increasing demand for satellite deployment and other aerospace services. By leveraging advanced technology and engineering expertise, iSpace China positions itself as a key player in the competitive landscape of commercial aerospace.

Beijing Yidaichu Technology

Series B in 2019
Beijing Yidaichu Technology Co., Ltd. is a software-as-a-service (SaaS) company that specializes in providing storage solutions for small and mid-sized e-commerce operators. Founded in 2015 and headquartered in Beijing, China, the company operates an online warehouse platform that integrates various storage resources. It employs a business model that includes self-operated warehouses, contracted management, and collaboration with traditional storage service providers to meet the needs of its clients. By streamlining storage operations, Beijing Yidaichu Technology supports e-commerce businesses in efficiently managing their inventory and logistics.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.